BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Hantavirus
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Thursday, May 21, 2026
Home
»
Newsletters
» BioWorld MedTech
BioWorld MedTech
Feb. 23, 2015
View Archived Issues
PwC report points out change in industry/FDA relationship
Read More
Inside the Beltway: Litwack says biggest concern for NGS is specific intended use
Read More
Financings: Saluda gets $10 million in new B round for chronic pain research
Read More
MDD Stock Report winners and losers
Read More
MDD Stock Report for Public Med-tech Companies
Read More
23andMe wins DTC approval for Bloom Syndrome genetic test
Read More
HIT Bits HIT Bits: Resolute H:ealth Hospital achieves HIMSS Analytics Stage 6 status
Read More
Restructuring: Integra Lifesciences cut 49 positions in Massachusetts facility late last year
Read More
Products
Read More
People in Places
Read More
MDD's Neurology Extra
Read More
Medtronic publishes five-year results from SANTE trial for DBS in epilepsy
Five-year results from a clinical study evaluating the use of deep brain stimulation (DBS) in adult epilepsy patients supports the use of DBS for treatment-resistant (refractory) epilepsy.
Read More
Perspectives Blog: Dam it: CMS plays the part of Hoover
Read More
